Moneycontrol PRO
HomeNewsBusinessAbraxis Bioscience LLC dismisses patent infringement complaint against SPARC

Abraxis Bioscience LLC dismisses patent infringement complaint against SPARC

"Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against Sun Pharma Advanced Research Co Ltd regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension)," the company said in a regulatory fling.

December 09, 2019 / 12:06 IST

Sun Pharma Advanced Research Co Ltd (SPARC) on Monday said Abraxis Bioscience LLC has dismissed the patent infringement complaint filed against the company.

"Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against Sun Pharma Advanced Research Co Ltd regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension)," the company said in a regulatory fling.

"We are very pleased that Abraxis Bioscience LLC has withdrawn its infringement claims paving the way for a successful launch as and when we receive necessary regulatory approvals," Sun Pharma Advanced Research Company Ltd CEO Anil Raghavan said.

SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay, the filing added.

Shares of SPARC were trading at Rs 159.35, up 3.68 percent on BSE.

PTI
first published: Dec 9, 2019 12:02 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347